Last reviewed · How we verify
NCT07279402
TRIMPACT: Real-World First-Line Atezolizumab Use in Stage IV NSCLC With PD-L1 ≥50%
trial in NSCLC Stage IV in 150 participants. Currently enrolling.
1 May 2027
Quick facts
| Lead sponsor | Antalya Training and Research Hospital |
|---|---|
| Status | Recruiting now |
| Study type | OBSERVATIONAL |
| Enrollment | 150 |
| Start date | 15 September 2025 |
| Primary completion | 1 May 2027 |
| Estimated completion | 1 October 2027 |
| Sites | 19 locations across Turkey (Türkiye) |
Conditions studied
- NSCLC Stage IV — all drugs for NSCLC Stage IV →
- PD-L1 Gene Mutation — all drugs for PD-L1 Gene Mutation →
- Atezolizumab — all drugs for Atezolizumab →
- Real World Study — all drugs for Real World Study →
Sponsor
Antalya Training and Research Hospital
Who can join
18 and older, any sex, with NSCLC Stage IV or PD-L1 Gene Mutation. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This prospective, multicenter, real-world observational study aims to evaluate the clinical outcomes of first-line atezolizumab monotherapy in patients with stage IV non-small cell lung cancer (NSCLC) with PD-L1 tumor cell expression ≥50% and no targetable mutations. The study aim to determine how atezolizumab performs in routine clinical practice with respect to survival, treatment response, and safety outcomes in this patient population in Türkiye.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT07279402
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for NSCLC Stage IV
Currently open trials in the same condition.
- NCT06401824 — Sacituzumab Govitecan and Bevacizumab for NSCLC Brain Metastases · Phase 2 · recruiting
- NCT06532149 — ERectile Dysfunctions, gOnadotoxicity and Sexual Health Assessment in Men With Lung Cancer · recruiting
- NCT06313541 — Treatment Response Adapted Hybrid Radiotherapy in Metastatic Non-small Cell Lung Cancer Receiving First-line Immunothera · Phase 2 · recruiting
- NCT06788366 — AI-HOPE Lung Cancer: Building a Predictive Tool for Metastatic Lung Cancer · recruiting
- NCT05816499 — Cadonilimab in Patients (Pts) With Advanced Non-small Cell Lung Cancer (NSCLC) · Phase 1, PHASE2 · active not recruiting
Other Antalya Training and Research Hospital trials
Trials by the same sponsor.
- NCT07480811 — The Effect of the DASH Diet on Clinical and Metabolic Parameters in Children With MASLD · NA · not yet recruiting
- NCT07453615 — Effect of AI(Artificial Intelligence)-Based Storytelling Video on Anxiety and Fear During Skin Prick Test in Children · NA · recruiting
- NCT07324655 — Association Between Office Ergonomics, Work Organization, and Musculoskeletal Complaints in Medical Secretaries · recruiting
- NCT07524933 — Comparison of the Effectiveness of Nerve Hydrodissection With Saline Injection of 5% Dextrose in Carpal Tunnel Syndrome. · NA · active not recruiting
- NCT07497295 — Ultrasound Assessment of Femoral Vein and Inferior Vena Cava Collapsibility to Predict Spinal Anesthesia-Induced Hypoten · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT07279402 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Antalya Training and Research Hospital
- Last refreshed: 12 December 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07279402.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing